Table 3.

Clinical Trials Testing BMS-986205 in Oncological Indications

Phase	Indication	Co-Therapy	Estimated or Actual Enrollment	Identifier	Status
Phase I	Multiple Malignancies	Itraconazole, Rifampin	53	NCT03346837	Completed in December 2017
Phase I	Advanced Cancer	Nivolumab	11	NCT03192943	Completed in December 2018
Phase I	Glioblastoma	Nivolumab, Radiation, Temozolomide	30	NCT04047706	Recruiting
Phase I	Advanced Cancer	Nivolumab, Relatlimab, Cabiralizumab, Ipilimumab, Radiotherapy	50	NCT03335540	Recruiting
Phase I/II	Malignant Solid Tumor	Nivolumab	17	NCT03792750	Completed in October 2021
Phase I/II	Hepatic Cell Carcinoma	Nivolumab	8	NCT03695250	Active, not recruiting
Phase I/II	Advanced bladder cancer	Nivolumab, Ipilimumab	516	NCT02658890	Active, not recruiting
Phase I/II	Advanced Cancer	Nivolumab, Ipilimumab, Relatlimab	184	NCT03459222	Recruiting
Phase II	NSCLC	Nivolumab, Ipilimumab, Relatlimab, Dasatinib	295	NCT02750514	Terminated in January 2020
Phase II	Bladder Cancer	Nivolumab, BCG	69	NCT03519256	Active, not recruiting
Phase II	Endometrial Cancer	Nivolumab	24	NCT04106414	Active, not recruiting
Phase II	Squamous Cell Carcinoma of the Head and Neck	Nivolumab	48	NCT03854032	Recruiting
Phase II	Renal Cell Carcinoma	Nivolumab, Ipilimumab, Relatlimab, BMS-813160	200	NCT02996110	Recruiting
Phase II	Gastric Cancer	Nivolumab, Ipilimumab, Relatlimab, Rucaparib	186	NCT02935634	Active, not recruiting
Phase II	Melanoma	Nivolumab, Ipilimumab	0	NCT04007588	Withdraw
Phase III	Advanced Melanoma	Nivolumab	20	NCT03329846	Completed in July 2020
Phase III	Bladder Cancer	Nivolumab, Gemcitabine, Cisplatin	976	NCT03661320	Recruiting
Phase III	Head and neck cancer	Nivolumab, Cetuximab, Chemotherapy	0	NCT03386838	Withdraw
Phase III	NSCLC	Nivolumab, Chemotherapy	0	NCT03417037	Withdraw

Note: The data were obtained from ClinicalTrials.gov database (https://www.clinicaltrials.gov).